Penn team-biotech col­lab­o­ra­tion high­lights promise of gene edit­ing in tar­get­ing PC­SK9, liv­er dis­eases

PC­SK9 car­dio drugs may still be hav­ing a tough time build­ing a mar­ket among stub­born pay­ers, but they’re nev­er­the­less con­sid­ered a re­mark­able ad­vance in slash­ing lev­els of LDL in at-risk pa­tients. And now one of the pi­o­neers in gene ther­a­py — work­ing in col­lab­o­ra­tion with an up­start biotech com­pa­ny — has com­plet­ed a pri­mate study to show that a unique gene edit­ing ap­proach can hit the same tar­get, with pos­i­tive ef­fects.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER